The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents
Abstract
OBJECTIVES: The Alexander Project is a continuing surveillance study, begun in 1992, examining the susceptibility of pathogens involved in adult community-acquired respiratory tract infections (CARTI) to a range of antimicrobial agents. MATERIALS AND METHODS: This study tested the susceptibility of isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected between 1998 and 2000 to 23 antimicrobials. Minimum inhibitory concentrations of agents were determined using the broth microdilution method and interpreted according to NCCLS and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: In total, 8882 isolates of S. pneumoniae, 8523 isolates of H. influenzae and 874 isolates of M. catarrhalis were collected during 1998-2000 from centres in 26 countries. The world-wide prevalence of penicillin resistance (penicillin MICs > or = 2 mg/l) in isolates of S. pneumoniae was 18.2% over the study period, and the prevalence of macrolide resistance (erythromycin MICs > or = 1 mg/l) in this pathogen was 24.6%. Over the study period, macrolide resistance exceeded penicillin resistance in 19 of the 26 countries included in the study. Of the non-fluoroquinolone agents, the only oral agents to which over 90% of S. pneumoniae isolates were susceptible at both NCCLS and PK/PD breakpoints were amoxicillin (95.1%) and co-amoxiclav (95.5-97.9%). The prevalence of fluoroquinolone-resistant S. pneumoniae (ofloxacin MICs > or = 8 mg/l) was 1.1%. Gemifloxacin was the most potent fluoroquinolone tested against S. pneumoniae (99.9% susceptible). In isolates of H. influenzae, beta-lactamase production was 16.9%, whereas the prevalence of beta-lactamase-negative, ampicillin-resistant strains was low (0.2%). beta-Lactamase production in M. catarrhalis world-wide remained high over the period studied (92.1%). Using PK/PD breakpoints, the most active non-fluoroquinolone agents against H. influenzae were ceftriaxone (100% susceptible), cefixime (99.8%) and co-amoxiclav (98.1-99.6%). Co-amoxiclav, cefdinir and cefixime (100%) were the most active beta-lactams against M. catarrhalis. Both H. influenzae and M. catarrhalis were highly susceptible to the fluoroquinolones. CONCLUSIONS: These data demonstrate the continued evolution of and geographical variation in bacterial resistance and highlight the need for appropriate prescribing of antimicrobials in CARTI, using agents with adequate activity, based on local susceptibility profiles and PK/PD parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
Chen, D. K., McGeer, A., de Azavedo, J. C., & Low, D. E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410403 · Cited by 987
Variation in antibiotic use in the European Union
Cars, O., Mölstad, S., & Melander, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04972-2 · Cited by 698
Sutcliffe, J., Tait-Kamradt, A., & Wondrack, L. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1817 · Cited by 619
Antimicrobial Treatment Guidelines for Acute Bacterial Rhinosinusitis
Partnership, S. A. A. H. (2004) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2003.12.003 · Cited by 535
Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia
Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C. S., Kibsey, P., Fleming, C., & Low, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012122 · Cited by 533
Hoban, D. J., Doern, G. V., Fluit, A. C., Roussel‐Delvallez, M., & Jones, R. N. (2001) · Clinical Infectious Diseases · doi:10.1086/320181 · Cited by 375
Felmingham, D., & Grüneberg, R. N. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.2.191 · Cited by 368
Lonks, J. R., Garau, J., Gomez, L., Xercavins, M., Ochoa de Echagüen, A., Gareen, I. F., Reiss, P. T., & Medeiros, A. A. (2002) · Clinical Infectious Diseases · doi:10.1086/341978 · Cited by 324
Jacobs, M. R., Bajaksouzian, S., Zilles, A., Lin, G., Pankuch, G. A., & Appelbaum, P. C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1901 · Cited by 317
Self-citation
Cited by
Clinical Practice Guideline (Update): Adult Sinusitis
Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Ashok Kumar, K., Kramper, M., Orlandi, R. R., Palmer, J. N., Patel, Z. M., Peters, A., et al. (2015) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599815572097 · Cited by 1,159
Clinical and economic burden of community-acquired pneumonia among adults in Europe
Welte, T., Torres, A., & Nathwani, D. (2012) · Thorax · doi:10.1136/thx.2009.129502 · Cited by 1,033
Clinical practice guideline: Adult sinusitis
Rosenfeld, R. M., Andes, D., Neil, B., Cheung, D., Eisenberg, S., Ganiats, T. G., Gelzer, A., Hamilos, D., Haydon, R. C., Hudgins, P. A., et al. (2007) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2007.06.726 · Cited by 907
Diagnosis and Management of Acute Otitis Media
Media, S. O. M. O. A. O. (2004) · Pediatrics · doi:10.1542/peds.113.5.1451 · Cited by 902
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial
Christ-Crain, M., Stolz, D., Bingisser, R., Müller, C., Miedinger, D., Huber, P. R., Zimmerli, W., Harbarth, S., Tamm, M., & Müller, B. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200512-1922oc · Cited by 884
Antimicrobial Treatment Guidelines for Acute Bacterial Rhinosinusitis
Partnership, S. A. A. H. (2004) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2003.12.003 · Cited by 535
Wald, E. R., Applegate, K. E., Bordley, C., Darrow, D. H., Glode, M. P., Marcy, S. M., Nelson, C. E., Rosenfeld, R. M., Shaikh, N., Smith, M. J., et al. (2013) · Pediatrics · doi:10.1542/peds.2013-1071 · Cited by 526
File, T. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15021-0 · Cited by 491
Antimicrobial Resistance in Haemophilus influenzae
Tristram, S., Jacobs, M. R., & Appelbaum, P. C. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-06 · Cited by 464
Self-citationGlobal Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use
Dalhoff, A. (2012) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2012/976273 · Cited by 354
Van Bambeke, F., Michot, J.-M., Van Eldere, J., & Tulkens, P. M. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01131.x · Cited by 342
Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications and usage
Huttner, A., Bielicki, J., Clements, M. N., Frimodt-Møller, N., Muller, A. E., Paccaud, J.-P., & Mouton, J. W. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.11.028 · Cited by 270
Kahlmeter, G., & Poulsen, H. O. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.09.013 · Cited by 256
White, A. R. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh050 · Cited by 198
Acute Bacterial Meningitis in Infants and Children: Epidemiology and Management
Agrawal, S., & Nadel, S. (2011) · Pediatric Drugs · doi:10.2165/11593340-000000000-00000 · Cited by 99
Metadata
- Authors
- Jacobs, M. R.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-07-01
- Volume
- 52
- Issue
- 2
- Pages
- 229-246
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2119658374
- Cited by
- 467
- References
- 32
- FWCI
- 39.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.